Biotechnology

Orgenesis

Orgenesis Inc. Degrading from OTCQX Due to Failure to File 10-K Report

Orgenesis Delays Quarterly Report Due to Resource Allocation Issues

Orgenesis released FY2024 Q3 earnings on November 13 (EST), actual revenue 347 K USD (forecast 18.5 M USD), actual EPS -1.9341 USD (forecast 1.7 USD)

Orgenesis released FY2024 cumulative Q3 earnings on November 13, 2024 (EST), with actual revenue of 734,000 USD and EPS of -7.1687

Orgenesis Inc. Announces Positive Results of CAR-T Therapy Study

Orgenesis received a NASDAQ hearing decision that the company has until October 14th to regain compliance with the minimum bid price and equity rules.

Orgenesis Inc has significant doubts about its ability to continue as a going concern

Profusa

EKSO Bionics

Antelope Enterprise

Oriental Culture

Cemtrex

Zhongchao

FLY-E

ON24

Dermata Therapeutics

Borealis Foods

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap